Subtype‐specific mutation of PPP2R1A in endometrial and ovarian carcinomas
暂无分享,去创建一个
A. Mes-Masson | S. Shah | D. Huntsman | J. Senz | S. Kalloger | N. Boyd | M. McConechy | M. Anglesio | Winnie Yang | C. Chow | A. Heravi‐Moussavi | G. Morin | M. Carey | J. McAlpine | J. Kwon | L. Prentice | C. Gilks | M. Mcconechy | Sohrab P. Shah
[1] R. Kempson,et al. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma , 1982, The American journal of surgical pathology.
[2] J. V. Bokhman. Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.
[3] A. Takai,et al. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. , 1988, The Biochemical journal.
[4] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[5] C. Slaughter,et al. Association of protein phosphatase 2A with polyoma virus medium tumor antigen. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[6] V. Abeler,et al. Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. , 1991, Gynecologic oncology.
[7] T. B. Miller,et al. Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A , 1990, Cell.
[8] J. Hofsteenge,et al. alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A have a similar 39 amino acid repeating structure. , 1990, Biochemistry.
[9] M. Mumby,et al. Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth. , 1993, Physiological reviews.
[10] J. Cain,et al. Uterine papillary serous carcinoma: patterns of metastatic spread. , 1994, Gynecologic oncology.
[11] M. Mumby,et al. Molecular model of the A subunit of protein phosphatase 2A: interaction with other subunits and tumor antigens , 1994, Journal of virology.
[12] R. Scully,et al. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. , 1995, Gynecologic oncology.
[13] J. Minna,et al. Alterations of the PPP2R1B gene in human lung and colon cancer. , 1998, Science.
[14] G. Walter,et al. Binding Specificity of Protein Phosphatase 2A Core Enzyme for Regulatory B Subunits and T Antigens , 1999, Journal of Virology.
[15] Brian A. Hemmings,et al. The Structure of the Protein Phosphatase 2A PR65/A Subunit Reveals the Conformation of Its 15 Tandemly Repeated HEAT Motifs , 1999, Cell.
[16] G. Russo,et al. Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms , 2000, Oncogene.
[17] Huong T. T. Pham,et al. Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the Aα subunit gene , 2001, Oncogene.
[18] J. Chan,et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. , 2003, Gynecologic oncology.
[19] R. Broaddus,et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. , 2003, Gynecologic oncology.
[20] Huong T. T. Pham,et al. Characterization of the Aalpha and Abeta subunit isoforms of protein phosphatase 2A: differences in expression, subunit interaction, and evolution. , 2003, The Biochemical journal.
[21] T. Kawabe. G2 checkpoint abrogators as anticancer drugs. , 2004, Molecular cancer therapeutics.
[22] J. Darbon,et al. Regulation of Chk2 phosphorylation by interaction with protein phosphatase 2A via its B' regulatory subunit , 2004, Biology of the cell.
[23] W. McCluggage,et al. WT‐1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma , 2004, Histopathology.
[24] C. van Hoof,et al. PP2A: the expected tumor suppressor. , 2005, Current opinion in genetics & development.
[25] M. Hendrickson,et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers , 2006, British Journal of Cancer.
[26] P. Rodriguez-Viciana,et al. Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control , 2006, Proceedings of the National Academy of Sciences.
[27] Yigong Shi,et al. Structure of the Protein Phosphatase 2A Holoenzyme , 2006, Cell.
[28] Hong Wang,et al. PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia , 2006, Clinical Cancer Research.
[29] Torsten Schwede,et al. BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .
[30] C. Sander,et al. Determinants of protein function revealed by combinatorial entropy optimization , 2007, Genome Biology.
[31] Wenqing Xu,et al. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme , 2007, Nature.
[32] J. Berek,et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. , 2008, American journal of obstetrics and gynecology.
[33] M. Carey,et al. Is adjuvant therapy necessary for Stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? , 2007, International Journal of Gynecologic Cancer.
[34] M. Stack,et al. SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells. , 2008, Gynecologic oncology.
[35] S. Leung,et al. Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.
[36] Ryan D. Morin,et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. , 2009, The New England journal of medicine.
[37] L. Ellenson,et al. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. , 2009, Gynecologic oncology.
[38] X. Chen,et al. PR55α, a Regulatory Subunit of PP2A, Specifically Regulates PP2A-mediated β-Catenin Dephosphorylation , 2009, The Journal of Biological Chemistry.
[39] W. McCluggage,et al. WT1, p53 and hormone receptor expression in uterine serous carcinoma , 2009, Histopathology.
[40] R. Bernards,et al. Protein phosphatase 2A regulatory subunits and cancer. , 2009, Biochimica et biophysica acta.
[41] Tian-Li Wang,et al. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.
[42] Ie-Ming Shih,et al. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.
[43] M. Nair,et al. Granulosa cell tumours of the ovary , 2010, The Australian & New Zealand journal of obstetrics & gynaecology.
[44] B. Clarke,et al. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type , 2010, Journal of Clinical Pathology.
[45] Mingming Jia,et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2009, Nucleic Acids Res..
[46] Richard A. Moore,et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.
[47] I. Yeh,et al. Molecular Profiling of Endometrial Malignancies , 2010, Obstetrics and gynecology international.
[48] S. Terlikowski,et al. Biomarkers as prognostic factors in endometrial cancer. , 2010, Folia histochemica et cytobiologica.
[49] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.